Incretin Atlas › Trials › GLORY-1
GLORY-1
Mazdutide · obesity
Design
- Molecule(s)
- Mazdutide
- Population
- obesity
- Official title
- A Study of IBI362 in Participants With Obesity or Overweight
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Phase
- 3
- Registry status
- completed · 2022-11 → 2023-08
- Participants
- 610
- Duration
- 48 weeks
- Registry
- NCT05607680
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| mazdutide 4 mg | obesity china | 48 | — | — | −11.0 % vs +0.3 % Δ −11.3 pp | — | 1.5 vs 1.0 | 11.3 vs 5.4 | 32.5 vs 5.9 | 26.1 vs 2.9 | 5.9 vs 6.3 | — | verified |
| mazdutide 6 mg | obesity china | 48 | — | — | −14.0 % vs +0.3 % Δ −14.3 pp | — | 0.5 vs 1.0 | 10.9 vs 5.4 | 50.5 vs 5.9 | 43.1 vs 2.9 | 4.0 vs 6.3 | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- mazdutide 4 mg: Shown at week 48, the end of randomised placebo-controlled treatment, so that weight and safety cover the same period (atlas rule, see Method). Primary end point at week 32 (treatment-policy): −10.09 % vs +0.45 % with placebo. Efficacy-estimand values and HbA1c are in the supplement only.
- mazdutide 6 mg: Shown at week 48, the end of randomised placebo-controlled treatment, so that weight and safety cover the same period (atlas rule, see Method). Primary end point at week 32 (treatment-policy): −12.55 % vs +0.45 % with placebo. Efficacy-estimand values and HbA1c are in the supplement only.
Verbatim quotes from the source (12)
- mazdutide 4 mg · weight_tp · Table 2 (week 48, key secondary end point)
| Percentage change in body weight from baseline to wk 48 (95% CI) — % | -11.00 (-12.27 to -9.73) | -14.01 (-15.36 to -12.66) | 0.30 (-0.98 to 1.58) |
- mazdutide 4 mg · ae_dc · Table 4
| Adverse event leading to discontinuation of mazdutide or placebo | 3 (1.5)
- mazdutide 4 mg · disc_any · Results, Participants, paragraph 1
trial regimen prematurely (23 participants [11.3%] in the 4-mg mazdutide group, 22 [10.9%] in the 6-mg mazdutide group, and 11 [5.4%] in the placebo group)
- mazdutide 4 mg · nausea · Table 4
| Nausea | 66 (32.5)
- mazdutide 4 mg · vomiting · Table 4
| Vomiting | 53 (26.1)
- mazdutide 4 mg · sae · Table 4
| Serious adverse event | 12 (5.9)
- mazdutide 6 mg · weight_tp · Table 2 (week 48, key secondary end point)
| Percentage change in body weight from baseline to wk 48 (95% CI) — % | -11.00 (-12.27 to -9.73) | -14.01 (-15.36 to -12.66) | 0.30 (-0.98 to 1.58) |
- mazdutide 6 mg · ae_dc · Table 4
| Adverse event leading to discontinuation of mazdutide or placebo | 3 (1.5) | 1 (0.5)
- mazdutide 6 mg · disc_any · Results, Participants, paragraph 1
trial regimen prematurely (23 participants [11.3%] in the 4-mg mazdutide group, 22 [10.9%] in the 6-mg mazdutide group, and 11 [5.4%] in the placebo group)
- mazdutide 6 mg · nausea · Table 4
| Nausea | 66 (32.5) | 102 (50.5)
- mazdutide 6 mg · vomiting · Table 4
| Vomiting | 53 (26.1) | 87 (43.1)
- mazdutide 6 mg · sae · Table 4
| Serious adverse event | 12 (5.9) | 8 (4.0)
Primary sources
- Ji L, Jiang H, Bi Y, Li H, Tian J, Liu D, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025;392(22):2215-2225. PMID: 40421736.
- Innovent Biologics (Suzhou) Co. Ltd.. A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of IBI362 in Chinese Participants With Obesity or Overweight (GLORY-1). ClinicalTrials.gov identifier NCT05607680. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05607680
How to cite this page
Medical Adviser's Group. Incretin Atlas: GLORY-1. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/glory-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.